Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations

被引：17

作者：

Langrand-Escure, J. ^{[1
]}

de Crevoisier, R. ^{[2
,3
]}

Llagostera, C. ^{[4
]}

Crehange, G. ^{[5
]}

Delaroche, G. ^{[1
]}

Lafond, C. ^{[2
,3
]}

Bonin, C. ^{[6
]}

Bideault, F. ^{[5
]}

Sargos, P. ^{[7
]}

Belhomme, S. ^{[7
]}

Pasquier, D. ^{[8
]}

Latorzeff, I ^{[9
]}

Supiot, S. ^{[4
]}

Hennequin, C. ^{[10
]}

机构：

[1] Inst Cancerol La Loire Lucien Neuwirth, 180 Bis,Ave Albert Raimond, F-42270 St Priest En Jarez, France

[2] Ctr Eugene Marquis, Dept Radiotherapie, Ave Bataille Flandres Dunkerque, F-35042 Rennes, France

[3] Inserm 1099, LTSI, 263 Ave Gen Leclerc, F-35042 Rennes, France

[4] Inst cancerol Ouest Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France

[5] Ctr Georges Francois Leclerc, Dept Radiotherapie, 1 Ave Prof Marion, F-21000 Dijon, France

[6] CHU Jean Minjoz, Serv Radiotherapie, 3 Blvd Alexandre Fleming, F-25000 Besancon, France

[7] Inst Bergonie, Dept Radiotherapie, 229 Cours Argonne, F-33000 Bordeaux, France

[8] Ctr Oscar Lambret, Dept Radiotherapie, 3 Rue Frederic Combemale, F-59020 Lille, France

[9] Clin Pasteur, Dept Oncol Radiotherapie, Bat Atrium,1 Rue Petite Vitesse, F-31300 Toulouse, France

[10] Hop St Louis, Serv Cancerol Radiotherapie, 1 Ave Claude Vellefaux, F-75010 Paris, France

来源：

CANCER RADIOTHERAPIE | 2018年 / 22卷 / 02期

关键词：

Prostate cancer; Hypofractionation; Radiotherapy; Image-guided radiation therapy; Recommendations; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; III RANDOMIZED-TRIAL; RADIATION-THERAPY; NON-INFERIORITY; PHASE-3; TRIAL; ACUTE TOXICITY; HIGH-RISK; ADENOCARCINOMA;

D O I：

10.1016/j.canrad.2017.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).

引用

页码：193 / 198

页数：6

共 50 条

[31] A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer
Casares-Magaz, Oscar
Muren, Ludvig P.
Pettersson, Niclas
Thor, Maria
Hopper, Austin
Knopp, Rick
Deasy, Joseph O.
Voth, Michael
Einck, John
Moiseenko, Vitali
PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2018, 7 : 65 - 69
[32] Dose constraints validation in moderate hypofractionation in localized prostate cancer
Maldonado, X.
Altabas, M.
Garre, J.
Vazquez, M.
Magrina, S.
Delgado, A.
Docampo, N.
Geng, A.
Hermida, M.
Sanchez-Artuno, D.
Giralt, J.
RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1113 - S1114
[33] Moderate hypofractionated radiotherapy in prostate cancer: a meta-analysis from randomized trials
Yin, Z.
Yuan, Z.
You, J.
RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S379 - S380
[34] Effectiveness of hypofractionated stereotactic radiotherapy: How much dose to control prostate cancer?
Wang, J. Z.
Yoshioka, Y.
Montebello, J. F.
Zhang, D.
Mayr, N. A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S351 - S351
[35] Early toxicity of moderate hypofractionated volumetric modulated Arc radiotherapy for localized prostate cancer
Kim, H. J.
Lee, J. S.
Kim, W. C.
INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2019, 17 (02): : 293 - 300
[36] Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity
Sundahl, Nora
De Meerleer, Gert
Villeirs, Geert
Ost, Piet
De Neve, Wilfried
Lumen, Nicolaas
De Visschere, Pieter
van Eijkerena, Marc
Fonteyne, Valerie
RADIOTHERAPY AND ONCOLOGY, 2016, 119 (03) : 398 - 404
[37] Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder
Hindson, Benjamin R.
Turner, Sandra L.
Millar, Jeremy L.
Foroudi, Farshad
Gogna, N. Kumar
Skala, Marketa
Kneebone, Andrew
Christie, David R. H.
Lehman, Margot
Wiltshire, Kirsty L.
Tai, Keen-Hun
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2012, 56 (01) : 18 - 30
[38] Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil (vol 67, pg 7, 2021)
Palhares, Daniel Moore Freitas
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2021, 67 (11): : 1742 - 1744
[39] Biological dose volume histograms during conformal hypofractionated accelerated radiotherapy for prostate cancer
Koukourakis, Michael I.
Abatzoglou, Ioannis
Touloupidis, Stavros
Manavis, Ioannis
MEDICAL PHYSICS, 2007, 34 (01) : 76 - 80
[40] Adjuvant hormonal therapy with goserilin improves survival in patients with locally advanced prostate cancer treated with radiotherapy - Results of phase III randomized trial of the EORTC Radiotherapy and Genito-urinary tract Cancer Cooperative Groups.
Bolla, M
Gonzalez, D
Kurth, KH
Warde, P
Dubois, JB
Mirimanoff, R
Keuppens, F
Bernier, J
Kuten, A
Pansadoro, V
Mattelaer, J
Cutajar, CL
Colette, L
Pierart, M
JOURNAL OF UROLOGY, 1998, 159 (05): : 131 - 131

← 1 2 3 4 5 →